JB Chemicals Strong Run Of Growth Continues With International Rise
Indian Firm Sees Full-Year Sales Up By 12%
JB Chemicals posted yet another strong quarter of growth to cap off its 2021 financial year, with broad revenue increases and a focus on ‘cost excellence’ leading to increased profit margins.
You may also be interested in...
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.
US private equity firm KKR is to acquire a majority stake in JB Chemicals, accelerating the Indian group's growth plans in branded formulations. Post a 54% stake acquisition for $414m via part-purchase from the founders and an open offer at INR745 per share, KKR's final stake could rise to 64.9% if founders offer more shares.
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.